Associated Papers
Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies.
Liu L et al.
Medcomm, 2025
41346570 (PubMed )
Supplement: MCO2-6-e70483-s002.xlsx › Tumour_cellularity
Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes.
Toriyama K et al.
The Journal of Pathology, 2025
40317966 (PubMed )
Supplement: PATH-266-337-s002.zip › path6432-sup-0004-TableS4.xlsx › PDAC-057-ad
Beyond BRAFV600E: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children.
Tang X et al.
Cancer Medicine, 2024
Sclerosing melanocytic tumors with MAP2K1 in-frame deletions and copy number gains in 15q: A distinctive pathway of nevogenesis.
Hamad J et al.
Journal of Cutaneous Pathology, 2024
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
Kemps PG et al.
Blood Advances, 2023
36083130 (PubMed )
Supplement: BLOODA_ADV-2022-007947-mmc1.pdf
Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.
Yang Y et al.
Journal of Cancer Research and Clinical Oncology, 2022
Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a Child.
Lekwuttikarn R et al.
Jama Dermatology, 2019
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R et al.
Blood, 2014
Select a paper to view details